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The complement anaphylatoxin, C5a, through binding to its receptors (C5aR or C5L2), has
important biological properties for recruitment and activation of phagocytes. C5a has been
identiﬁed as a powerful modulator of Toll-like receptor-induced cytokine and chemokine
production by macrophages. Both the complement system and the interleukin (IL)-17
cytokine family protect against extracellular pathogens by enhancing innate immune func-
tions. On the basis of its concentration, C5a can either positively or negatively modulate
the production by macrophages of IL-17 family members as well as IL-23 via the phos-
phatidylinositol 3-kinase/Akt signaling cascade. C5a can also affect the production and
maintenance of IL-17-producing T cells. Using C5a, C5aR, or C5L2 deﬁciency or block-
ade, IL-17/IL-23 production and/or IL-17-dependent disease progression has been shown
to be substantially modiﬁed. The contributions of C5a interaction with its receptors in
the production of IL-17/IL-23 and promotion of IL-17-dependent immune responses are
reviewed.
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INTRODUCTION
The complement system provides an important ﬁrst line of
defense against extracellular pathogens such as bacteria and fungi.
It is composed of several membrane-bound and plasma reg-
ulators and activators that can interact with a myriad of cell
types. The consequences of complement activation vary depend-
ing on the physiological context and timing during an immune
(innate or adaptive) response. The effects of its products on com-
plement receptors of immune and phagocytic cells are equally
diverse. Complement activation exerts a wide range of effects that
makes it ideal as both an effector mechanism and coordinator of
immune/inﬂammatory responses. In this review, we summarize
recent ﬁndings showing that interleukin (IL)-17 and IL-23 are
modulated by the complement activation product, C5a.
COMPLEMENT ACTIVATION AND EFFECTORS
The activation of the complement cascade is requisite for its
involvement in immune responses. Complement activation is
thought of mainly as occurring in the intravascular space; however,
the components are present not only in the circulation, but also in
almost every tissue and ﬂuid. Complement can be activated by any
of three different pathways (classical, alternative, or lectin), which
converge on the cleavage of C3 into C3a and C3b (for a recent
review, see Sarma and Ward, 2011). C3a is an anaphylatoxin that
affects cellular functions through interactions with its receptor
C3aR. C3b acts as an opsonin and also combines with other com-
ponents to form the C5 convertase that cleaves C5 into C5a and
C5b. C5b, in concert with C6–C9 forms the terminal membrane
attack complex. C5a is an anaphylatoxin and also has the ability to
act as an activator and chemoattractant for phagocytes by bind-
ing to its receptors, C5aR and C5L2. C5a can also alter cytokine
and chemokine production bymacrophages and other cells. Thus,
complement activation is an important ﬁrst line of defense against
pathogens; however, complement components have the ability
to substantially alter immune responses by modulating the local
cytokine milieu.
THE IL-17 FAMILY OF CYTOKINES
IL-17 has been reported to contribute to disease severity in sev-
eral models of autoimmune and chronic inﬂammatory diseases
includingmultiple sclerosis and collagen-induced arthritis (Nakae
et al., 2003; Langrish et al., 2005). Furthermore, IL-17 may be a
signiﬁcant driving force in many acute inﬂammatory reactions
including sepsis (Flierl et al., 2008), ischemia-reperfusion injury
(Xue et al., 2011), and acute lung injury (Ferretti et al., 2003).
The IL-17 family is comprised of six cytokines (IL-17A–F) that
have a similar structure highlighted by four conserved cysteine
residues. IL-17was originally described as being produced primar-
ily by T helper 17 (TH17) cells, but innate immune/inﬂammatory
cells have also been shown to release substantial amounts. IL-17
members have an important role in generating and propagating
immune responses, including inducing and enhancing cytokine
[IL-6, tumor necrosis factor (TNF), IL-1β], and chemokine (IL-8,
CCL2) production (Fossiez et al., 1996). The predominant IL-
17 family members are IL-17A (herein referred to as IL-17) and
IL-17F,which share about 50% sequence identity and are often co-
expressed. Although the functions of IL-17 and IL-17F are similar,
IL-17 is usuallymore potent at promoting inﬂammation, and their
effects are not always identical (for a review, see Korn et al., 2009).
The IL-17 family binds to a group of ﬁve receptors that have
distinct ligand speciﬁcities. The best described IL-17 receptor is
IL-17R, which binds both IL-17A and IL-17F. The other IL-17
receptors are IL-17RB–E, each containing their own distinct IL-
17 binding speciﬁcities. IL-17 receptors are broadly expressed not
only by leukocytes, but also by endothelial cells and ﬁbroblasts,
amongst others (Fossiez et al., 1996). Therefore, the IL-17 family
of cytokines contains several related cytokines and receptors that
are generally pro-inﬂammatory.
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IL-23 is a heterodimer composed of p19 and p40 subunits,
of which the p40 subunit is shared with IL-12 (Oppmann et al.,
2000). IL-23 is most prominently known as a driver of TH17 cell
expansion and IL-17 production (Aggarwal et al., 2003). Besides a
role in promoting TH17 cell expansion, IL-23 induces IL-1, TNF,
and IL-6 from innate immune cells (Murphy et al., 2003; Uhlig
et al., 2006). Importantly, IL-23 also promotes IL-17 production
from γδT cells and natural killer (NK) T cells (Sutton et al., 2009;
Liu et al., 2011b). Therefore, IL-23 has a prominent role in pro-
moting IL-17 production by both TH17 cells and innate immune
cells.
MECHANISMS GOVERNING IL-17 PRODUCTION BY LEUKOCYTES
The requirements for the generation of TH17 cells have been
intensively studied, and depend primarily on the presence of
transforming growth factor (TGF)-β and IL-6 during lymphocyte
activation (for a review, see McGeachy and Cua, 2008). Also, later
stages of TH17 cell development and maximum IL-17 production
are dependent on IL-23. While these pathways have become quite
well deﬁned in recent years, the pathways responsible for IL-17
production by leukocytes of innate immune lineages remain less
clear. Evidence for innate sources of IL-17 came with the obser-
vation that IL-17 was present in recombination-activating gene
(RAG)-deﬁcientmice,which lackmatureB andT cells (Uhlig et al.,
2006). Further evidence has accumulated showing that substantial
amounts of IL-17 can be produced by γδT cells, NK T cells, Paneth
cells, mast cells, neutrophils, and macrophages (Lockhart et al.,
2006;Michel et al., 2007; Takahashi et al., 2008; Hueber et al., 2010;
Li et al., 2010; Bosmann et al., 2012). We and others have reported
that activation of Toll-like receptor 4 (TLR4) on mouse peritoneal
and alveolar macrophages results in the MyD88-dependent pro-
duction of IL-17 and IL-17F (Gu et al., 2008; Bosmann et al., 2011,
2012). This effect appears to be TLR4-speciﬁc, because activa-
tion of other TLRs does not result in the production of these
cytokines. However, one report has described the generation of
IL-17 in response to TLR2 activation by chitin (Da Silva et al.,
2008). The molecular mechanisms that regulate IL-17 production
by innate immune cells remain otherwise undeﬁned. Lympho-
cytic innate cells (e.g., NK T cells, γδT cells) appear to rely on
the transcription factor RORγt for IL-17 production, much like
conventional TH17 cells (Cua and Tato, 2010). Recently, mast
cells were also shown to depend on RORγt for IL-17 gene tran-
scription (Hueber et al., 2010). Interestingly, RORγt was elevated
in IL-10−/− macrophages and enhanced IL-17 production (Gu
et al., 2008). However, TLR4-activated wild type macrophages,
which produced lower levels of IL-17, had no detectable
RORγt expression (Gu et al., 2008). Therefore, the transcrip-
tion factors relevant for IL-17 induction by macrophages remain
unclear.
MODULATION OF IL-17 AND IL-23 BY C5a
MODULATION OF INNATE IL-17 AND IL-23 PRODUCTION BY C5a
The complement activationproduct, C5a, has been shown tomod-
ulate IL-17 production by innate immune cells. We have recently
reported that C5a alters the production of both IL-17 and IL-
17F, and IL-23 in LPS-stimulated macrophages. Speciﬁcally, the
production of IL-17 and IL-23 by TLR4-stimulated macrophages
in vitro was signiﬁcantly reduced in a dose-dependent manner in
the concomitant presence of C5a (Bosmann et al., 2012). Using
genetically targeted C5aR- or C5L2-deﬁcient mice, it was shown
that the inhibitory effects of C5a on IL-17 and IL-23 production
aremediated exclusively byC5aR.Mechanistically, themodulatory
effects of C5a on IL-17 and IL-23 appear to be mediated indi-
rectly by C5aR activation-induced enhancement in IL-10 release,
which reduces IL-17 and IL-23 in an autocrine/paracrine man-
ner; however, a direct mechanism was not ruled out. In agreement
with these ﬁndings, C5a inhibited IL-23 release by TLR-activated
human monocyte-derived dendritic cells (DCs; Zaal et al., 2012).
Interestingly, while C5a down-regulated IL-17 and IL-23 produc-
tion by macrophages, it has been shown to enhance the release
of IL-17F. Speciﬁcally, while TLR4 activation induces production
of IL-17F by macrophages in vitro, the co-presence of increasing
concentrations of C5a results in a synergistic increase in IL-17F
release (Bosmann et al., 2011). The heightened release of IL-17F is
mediated through combined enhancement of the phosphatidyli-
nositol 3-kinase (PI3K)/Akt pathway by C5a and LPS. Taken
together, these studies reveal that C5a modulates IL-17, IL-17F,
and IL-23 production by macrophages, which has the potential to
signiﬁcantly alter immune responses.
Studies have shown that the production of IL-17 by γδTcells can
also be affected by C5a. Activation of C5aR on γδT cells enhanced
IL-17 production following CD3 ligation in vitro, through a
PI3K/Akt-dependent manner (Han et al., 2011). Furthermore,
IL-17 production by γδT cells can be enhanced indirectly. Specif-
ically, the activation of DCs by C5a promoted the production
of IL-17 by γδT cells, which appeared to be the result of
enhanced IL-6 production by C5a-activated DCs (Xu et al., 2010).
These results indicate that C5a signiﬁcantly alters IL-17 produc-
tion by cells of the innate immune system, as summarized in
Figure 1.
In addition to modulating IL-17 production by innate leuko-
cytes in vitro, C5a can modulate TLR-induced IL-17 production
in vivo. Speciﬁcally, co-injection of C5a and Pam3CSK4 (pro-
totypic TLR2 ligand) resulted in a synergistic enhancement in
IL-17 production compared to each agonist alone when injected
into the gingiva of mice (Abe et al., 2012). In the same study,
administration of a C5aR antagonist resulted in reduced pro-
duction of IL-17 during two models of periodontitis. There-
fore, modulation of the complement system may be a potential
therapeutic target for modulating (either up or down) innate
immune cell-derived IL-17 production and thus innate immune
responses.
MODULATION OF IL-17 IN ACQUIRED IMMUNITY BY C5a
C5a has been shown tomodulate the phenotype of T cells through
indirect mechanisms, owing to the fact that C5a receptors are
little, if at all, expressed on mature T cells (Dunkelberger et al.,
2012), although antigen-stimulated CD4+ T cells may have low
levels of C5aR expression (Strainic et al., 2008). Importantly, C5a
alters cytokine production by DCs and tissue macrophages in a
manner that can promote or inhibit the generation of TH17 cells.
Speciﬁcally, the cytokine milieu produced by TLR2- and OVA-
activated C5aR−/− DCs was substantially different fromwild type
cells, and included increased production of TGF-β, IL-6, IL-21,
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FIGURE 1 | Modulation of innate immune cell-derived IL-17 by C5a. (A)
LPS-activated macrophages produce IL-17, IL-17F, and IL-23. C5aR activation
has been shown to enhance IL-17F while reducing IL-17 and IL-23 production
by macrophages. (B) Activated γδT cells produce IL-17 which is enhanced
directly or indirectly by C5a.
and IL-23 in vitro, cytokines important for TH17 differentiation
(Weaver Jr. et al., 2010). Furthermore, DC or macrophage C5aR
deﬁciency or blockadewith aC5aR antagonist promoted TH17 cell
differentiation both in vitro and in vivo (Fang et al., 2009; Weaver
Jr. et al., 2010). In agreement with these ﬁndings, another report
determined that IL-17 levels in experimental asthma are reduced
by signaling through C5aR (Lajoie et al., 2010). Speciﬁcally, anti-
bodyblockadeor genetic disruptionof C5aRorC5 enhancedTH17
cell differentiation following house dust mite extract challenge. In
the same study, the genetic absence of C3aR reduced IL-17 pro-
duction, indicating opposite effects of C5aR and C3aR. The other
C5a receptor, C5L2, has also been shown to modulate IL-17 pro-
duction by T cells. C5L2−/− DCs released substantial amounts of
IL-23 following stimulation with house dust mite allergen in vitro,
an effect not observed in wild type DCs (Zhang et al., 2010). Fur-
thermore, C5L2−/− DCs signiﬁcantly enhanced the production
of TH17 cells and IL-17 in vitro and in vivo during experimental
asthma, compared towild type controls (Zhang et al., 2010). Taken
together, these reports demonstrate that the absence of eitherC5aR
or C5L2 on DCs enhances TH17 differentiation by altering the
local cytokine milieu. Therefore, C5a-induced activation of DCs
inhibits the generation of TH17 cells and IL-17 production both
in vitro and in vivo.
While C5a appears to reduce lymphocyte-derived IL-17, con-
ﬂicting data has been generated. Speciﬁcally, during complement-
dependent experimental autoimmune arthritis, C5aR deﬁciency
blocked the generation and expansion of TH17 cells, which
suppressed the development of arthritis (Hashimoto et al., 2010).
This effect was determined to be the consequence of modulation
of local cytokine production by tissue resident macrophages to
promote a TH17-type response. Similarly, C5a has been reported
to enhance IL-17 production by human T cells in vitro, which is
dependent on enhanced IL-6 and IL-1β expression from mono-
cytes (Liu et al., 2011a). Therefore, C5a has also been shown to
promote TH17 cell differentiation and enhance IL-17 production
by T cells.
Taken together, these reports demonstrate that the effect of
C5a on T cell-derived IL-17 remains controversial, as summarized
in Figure 2. It is apparent that the actions of C5a are context-
dependent andmaybe reliant on the target cell and the co-presence
of other activators or regulators. Therefore, further study is needed
to delineate the mechanism of C5a-induced changes in IL-17
during acquired immune responses.
C5a-MEDIATED MODULATION OF THE IL-17 FAMILY IN VIVO
Endotoxemia and sepsis
Evidence has accumulated that reveals a role of C5a for modu-
lating IL-17 during immune responses in vivo. IL-17 has a key
role during endotoxemia and sepsis, evidenced by the ﬁnding
that antibody blockade of IL-17 reduces mortality following lethal
LPS administration or cecal ligation and puncture (CLP; Flierl
et al., 2008; Bosmann et al., 2012). Importantly, C5aR−/− mice
displayed signiﬁcantly enhanced serum IL-17 production during
endotoxemia, indicating that C5aR activation limits plasma IL-
17 levels. In contrast to IL-17, IL-17F in plasma is reduced by
blocking C5a during endotoxemia (Bosmann et al., 2011). These
observations likely result from the ﬁnding that signiﬁcant produc-
tion of IL-17 during endotoxemia is frommacrophages (Bosmann
et al., 2012), and C5a differentially affects macrophage-derived IL-
17 and IL-17F as described above (see Modulation of IL-17 in
Acquired Immunity by C5a). IL-17 production during CLP is also
altered by C5a. Speciﬁcally, blockade of C5a signiﬁcantly reduced
IL-17 in plasma, and also reduced mortality during CLP (Xu et al.,
2010). In the same report, γδT cells were determined to be the pre-
dominant source of IL-17. Therefore, C5a can signiﬁcantly alter
IL-17 levels during endotoxemia and sepsis.
Autoimmune and chronic inﬂammatory diseases
IL-17 has been shown to have a prominent role in autoimmune
and chronic inﬂammatory diseases such as asthma, rheumatoid
arthritis, and experimental autoimmune encephalomyelitis (EAE;
Chabaud et al., 1999; Komiyama et al., 2006; Kudo et al., 2012).
Importantly, C5a has been shown tomodulate IL-17 levels in these
diseases. In asthma, the production of IL-17 and airway hyper-
responsiveness are regulated, in part, by C5a. A negative linear
correlation between serum C5a concentration and lung TH17 cell
numbers was observed following house dust mite extract chal-
lenge (Lajoie et al., 2010). The same report demonstrated that
mice deﬁcient in C5 produced signiﬁcantly more IL-17A during
experimental asthma. Antibody blockade of C5aR enhanced TH17
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FIGURE 2 | Modulation ofT cell-derived IL-17 by C5a. C5a modulates TH17 cell differentiation by altering the local production of IL-23, IL-6, andTGF-β by DCs
or macrophages. C5a can either enhance or inhibit TH17 cell differentiation depending on the inﬂammatory context.
cell numbers. Furthermore, C5L2−/− mice have increased pul-
monary IL-17, indicating a role for the second C5a receptor in
vivo (Zhang et al., 2010). Therefore, C5a negatively regulates IL-17
production during experimental asthma, which results in reduced
airway hyper-responsiveness.
C5a also modulates IL-17 during experimental arthritis. In a
complement-dependent autoimmune arthritis model, C5a acti-
vated tissue macrophages to produce IL-6 and drive TH17 cell
differentiation (Hashimoto et al., 2010). Furthermore, C5aR deﬁ-
ciency resulted in signiﬁcant reductions in auto-reactive TH17
cells and disease severity. Therefore, C5a modulates IL-17 during
autoimmune arthritis. However, the role of C5a on modulat-
ing IL-17 during other arthritis models (e.g., collagen-induced)
has not been demonstrated, which limits the scope of this single
report.
Complement has been reported to modulate IL-17 during
EAE. Speciﬁcally, the genetic ablation of decay accelerating factor
(DAF), a complement regulatory protein that blocks the gen-
eration of C3a and C5a by blocking C3 convertase results in
enhanced TH17 cell production and increased injury during EAE
(Liu et al., 2008). Importantly, the absence of either C5aR or
C3aR reduced TH17 cell differentiation (Liu et al., 2008). Fur-
thermore, either augmenting DAF levels using over-expressing
transgenicmice or use of FUT-175, theC3/C5 convertase inhibitor,
reduced EAE severity and TH17 cell numbers (Li et al., 2009a,b).
Taken together, these reports indicate that complement can
enhance TH17 cell accumulation and disease severity during
EAE. However, the exact mechanism of this modulation remains
unclear.
CONCLUSION
Since the discovery of IL-17, it has become clear that speciﬁc
pathogens trigger IL-17-dependent responses and that robust IL-
17 production is required for the efﬁcient clearance of many
pathogens. The mechanism responsible for this phenomenon
remains unclear, but appears to be dependent on the ability of spe-
ciﬁc pathogen-associated molecular pattern (PAMP)-dependent
signals to promote the production of IL-17 and/or IL-17-
enhancing cytokines (e.g., IL-23) by innate immune cells. The
role of complement in modulating IL-17-dependent inﬂamma-
tion is only now becoming apparent. Due to the fact that the
effects of C5a on IL-17 vary signiﬁcantly based on the inﬂamma-
tory context and target cell type, making generalized conclusions
about these interactions are difﬁcult. Many questions regarding
C5a-induced modulation of IL-17 remain, and the relationship
between these two mediators deserves signiﬁcant attention. The
clinical importance of both IL-17 and C5a for a myriad of inﬂam-
matory diseases has been extensively demonstrated. Therefore, an
understanding of the relationship between the two mediators has
signiﬁcant clinical implications for the treatment of both acute
and chronic inﬂammatory diseases.
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